Bruno Rivas-Santiago

Dr. Bruno Rivas-Santiago

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
BRBruno Rivas-Santiago
Bruno Rivas-Santiago
CRCésar Enrique Rivas-Santiago
César Enrique Rivas-Santiago
JDJulio Enrique Delgado
Julio Enrique Delgado
JLJuan C. León–Contreras
Juan C. León–Contreras
RHRobert E. W. Hancock
Robert E. W. Hancock
Rogelio Hernández-PandoRogelio Hernández-Pando
Rogelio Hernández-Pando

17 May 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
YJYolanda M. Jacobo-Delgado
Yolanda M. Jacobo-Delgado
ARAdrian Rodríguez-Carlos
Adrian Rodríguez-Carlos
CSCarmen J. Serrano
Carmen J. Serrano
BRBruno Rivas-Santiago
Bruno Rivas-Santiago
Mycobacterium tuberculosis (Mtb) is one of the most important infectious agents worldwide and causes more than 1.5 million deaths annually. To make matters worse, the drug resistance among Mtb strains has risen substantially in the last few decades. Nowadays, it is not uncommon to find patients infected with Mtb strains that are virtually resistant to all antibiotics, which has led to the urgent search for new molecules and therapies. Over previous decades, several studies have demonstrated the efficiency of antimicrobial peptides to eliminate even multidrug-resistant bacteria, making them outstanding candidates to counterattack this growing health problem. Nevertheless, the complexity of the Mtb cell wall makes us wonder whether antimicrobial peptides can effectively kill this persistent Mycobacterium. In the present review, we explore the complexity of the Mtb cell wall and analyze the effectiveness of antimicrobial peptides to eliminate the bacilli.

22 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IGIrma González-Curiel
Irma González-Curiel
VTValentin Trujillo
Valentin Trujillo
AMAlejandra Montoya-Rosales
Alejandra Montoya-Rosales
KRKublai Rincon
Kublai Rincon
BRBruno Rivas-Calderon
Bruno Rivas-Calderon
BRBruno Rivas-Santiago
Bruno Rivas-Santiago
Diabetic foot ulcers (DFU) are one of the most common diabetes-related cause of hospitalization and often lead to severe infections and poor healing. It has been recently reported that patients with DFU have lower levels of antimicrobial peptides (AMPs) at the lesion area, which contributes with the impairment of wound healing. The aim of this study was to determine whether 1,25-dihydroxyvitamin D3 (1,25 (OH)2 D3) and L-isoleucine induced HBD-2 and LL-37 in primary cultures from DFU. We developed primary cell cultures from skin biopsies from 15 patients with DFU and 15 from healthy donors. Cultures were treated with 1,25 (OH)2D3 or L-isoleucine for 18 h. Keratinocytes phenotype was identified by western blot and flow cytometry. Real time qPCR for DEFB4, CAMP and VDR gene expression was performed as well as an ELISA to measure HBD-2 and LL-37 in supernatant. Antimicrobial activity, in vitro, wound healing and proliferation assays were performed with conditioned supernatant. The results show that primary culture from DFU treated with 1,25(OH)2D3, increased DEFB4 and CAMP gene expression and increased the production of HBD-2 and LL-37 in the culture supernatant. These supernatants had antimicrobial activity over E. coli and induced remarkable keratinocyte migration. In conclusion the 1,25(OH)2D3 restored the production of AMPs in primary cell from DFU which were capable to improve the in vitro wound healing assays, suggesting their potential therapeutic use on the treatment of DFU.

1 December 2015 in Infection and Immunity
Verified
Journal Article
Open access
PDF file
FTFlor Torres-Juarez
Flor Torres-Juarez
ACAlbertina Cardenas-Vargas
Albertina Cardenas-Vargas
AMAlejandra Montoya-Rosales
Alejandra Montoya-Rosales
IGIrma González-Curiel
Irma González-Curiel
MGMariana H. Garcia-Hernandez
Mariana H. Garcia-Hernandez
BRBruno Rivas-Santiago
Bruno Rivas-Santiago
Tuberculosis is one of the most important infectious diseases worldwide. The susceptibility to this disease depends to a great extent on the innate immune response against mycobacteria. Host defense peptides (HDP) are one of the first barriers to counteract infection. Cathelicidin (LL-37) is an HDP that has many immunomodulatory effects besides its weak antimicrobial activity. Despite advances in the study of the innate immune response in tuberculosis, the immunological role of LL-37 during M. tuberculosis infection has not been clarified. Monocyte-derived macrophages were infected with M. tuberculosis strain H37Rv and then treated with 1, 5, or 15 μg/ml of exogenous LL-37 for 4, 8, and 24 h. Exogenous LL-37 decreased tumor necrosis factor alpha (TNF-α) and interleukin-17 (IL-17) while inducing anti-inflammatory IL-10 and transforming growth factor β (TGF-β) production. Interestingly, the decreased production of anti-inflammatory cytokines did not reduce antimycobacterial activity. These results are consistent with the concept that LL-37 can modulate the expression of cytokines during mycobacterial infection and this activity was independent of the P2X7 receptor. Thus, LL-37 modulates the response of macrophages during infection, controlling the expression of proinflammatory and anti-inflammatory cytokines.

1 November 2009 in Infection and Immunity
Verified
Journal Article
Closed access
BRBruno Rivas-Santiago
Bruno Rivas-Santiago
CSCarmen J. Serrano
Carmen J. Serrano
JEJ. Antonio Enciso-Moreno
J. Antonio Enciso-Moreno
In the last few years, the great impact of antimicrobial peptides on infectious disease susceptibility and natural resistance has been reported. In some cases, susceptibility to diseases is related to antimicrobial peptide polymorphisms and gene copy numbers, but for the vast majority of infectious diseases, these phenomena need to be elucidated. This review is focused on the current knowledge about susceptibility and resistance conferred by genetic variations in antimicrobial peptide expression in infectious diseases.

1 January 2012 in Journal of Dermatological Science
Verified
Journal Article
Closed access
BRBruno Rivas-Santiago
Bruno Rivas-Santiago
VTValentín Trujillo
Valentín Trujillo
AMAlejandra Montoya
Alejandra Montoya
IGIrma González-Curiel
Irma González-Curiel
JDJulio Enrique Delgado
Julio Enrique Delgado
Rogelio Hernández-PandoRogelio Hernández-Pando
Rogelio Hernández-Pando